Catalent Applied Drug Delivery Institute Appoints New Advisory Board Member - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Applied Drug Delivery Institute Appoints New Advisory Board Member



The Catalent Applied Drug Delivery Institute, an institute formed by Catalent Pharma Solutions, to promote collaboration between industry and academia, provide applied drug-delivery education and training, and advanced drug delivery, has appointed Claus-Michael Lehr, Head of the Department of Biopharmaceutics and Pharmaceutical Technology, Saarland University, Germany and Co-founder and Head of the Department “Drug Delivery” of the Helmholtz Institute for Pharmaceutical Research Saarlandto the institute’s advisory board.

Professor Lehr has t more than 15 years researching ways to overcome biological barriers to effective drug delivery and the development and formulation of appropriate carriers to transport active pharmaceutical and biopharmaceutical molecules to desired targets. He has co-authored many publications on the development of sophisticated in-vitro models that represent the epithelial cells and tissues concerned in transport, and the application of nanotechnology to improve in-vivo delivery to such therapeutic targets.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here